x

Posted 03 February, 2023

Vyant Bio, Inc. appointed Andrew D.C. LaFrence as new CEO

Nasdaq:VYNT appointed new Chief Executive Officer Andrew D.C. LaFrence in a 8-K filed on 03 February, 2023.


  Andrew D.C. LaFrence, the Company's Chief Financial Officer, will assume the role of President and Chief Executive Officer following Mr. Roberts' departure.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Vyant Bio, Inc.
Health Care/Life Sciences • Biotechnology
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.
Market Cap
N/A
View Company Details
Vyant Bio, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 31, 2023, Vyant Bio, Inc. (the "Company"), John A. Roberts and Robert T. Fremeau, Jr., agreed in principle that Mr. Roberts and Dr. Fremeau would step down as President and Chief Executive Officer and Chief Scientific Officer, respectively, of the Company, effective as of February 3, 2023, and their employment agreements, which are filed as exhibits to the Company's Annual Report on Form 10-K for the year ended December 31, 2021, would be deemed terminated as of that date by the Company without cause for purposes of determining severance thereunder. Such agreement was not the result of any disagreement Mr. Roberts or Dr. Fremeau had with the Company on any matters relating to the Company's operations, policies or practices. Mr. Roberts will remain a member of the Board of Directors of the Company.


Andrew D.C. LaFrence, the Company's Chief Financial Officer, will assume the role of President and Chief Executive Officer following Mr. Roberts' departure. Mr. LaFrence became Chief Financial Officer upon the Company's merger with StemoniX, Inc. on March 30, 2021, pursuant to the terms of an employment agreement, dated March 30, 2021, which will remain in effect. Mr. LaFrence's biography can be found in the Company's proxy statement filed with the SEC on June 14, 2022, which is incorporated herein by reference.